Showing 1 - 20 results of 39,899 for search '(( 50 ((_ decrease) OR (a decrease)) ) OR ((( 50 mg decrease ) OR ( _ pre decrease ))))*', query time: 0.95s Refine Results
  1. 1

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  2. 2

    Proportion of participants with sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment value and to < 8100 mf/ml. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Proportion of participants with sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment value and to < 8100 mf/ml.…”
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    Decrease of synchronization measures during a pre-ictal interval. by Christian Meisel (46720)

    Published 2013
    “…Averages over the first 150000 sample points of each time series indicate a distinct decrease of each synchronization measure during the pre-ictal interval (bottom row). …”
  10. 10
  11. 11
  12. 12

    Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

    Published 2024
    “…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20